Accelerate Diagnostics (AXDX) Scheduled to Post Earnings on Thursday

Accelerate Diagnostics (NASDAQ:AXDX) will be releasing its earnings data after the market closes on Thursday, March 28th. Analysts expect Accelerate Diagnostics to post earnings of ($0.62) per share for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

Accelerate Diagnostics Price Performance

NASDAQ AXDX opened at $0.96 on Wednesday. Accelerate Diagnostics has a 1-year low of $0.83 and a 1-year high of $11.90. The business has a 50 day simple moving average of $1.15 and a two-hundred day simple moving average of $3.75. The stock has a market capitalization of $13.99 million, a PE ratio of -0.18 and a beta of 0.51.

Analysts Set New Price Targets

Separately, StockNews.com started coverage on shares of Accelerate Diagnostics in a research note on Tuesday, March 19th. They set a “hold” rating on the stock.

Institutional Investors Weigh In On Accelerate Diagnostics

Several large investors have recently added to or reduced their stakes in AXDX. Swiss National Bank boosted its stake in Accelerate Diagnostics by 19.0% during the first quarter. Swiss National Bank now owns 85,300 shares of the medical research company’s stock worth $123,000 after buying an additional 13,600 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Accelerate Diagnostics by 17.9% during the 1st quarter. JPMorgan Chase & Co. now owns 418,359 shares of the medical research company’s stock worth $602,000 after purchasing an additional 63,513 shares during the period. HighTower Advisors LLC boosted its stake in shares of Accelerate Diagnostics by 115.6% during the 1st quarter. HighTower Advisors LLC now owns 37,302 shares of the medical research company’s stock worth $53,000 after purchasing an additional 20,000 shares during the period. Bank of Montreal Can bought a new position in Accelerate Diagnostics during the 1st quarter valued at about $27,000. Finally, Baird Financial Group Inc. raised its position in Accelerate Diagnostics by 15.5% in the 1st quarter. Baird Financial Group Inc. now owns 1,741,547 shares of the medical research company’s stock worth $2,508,000 after purchasing an additional 233,478 shares during the period. 17.14% of the stock is owned by institutional investors.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.